Pancreatic Cancer
RMC-6236-304 RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC).
- Details
ClinicalTrials.gov ID:
NCT07252232
Diagnosis Type:
NA
USOR Number:
- Address
,
P: